Department of Surgery, Kashiwara Municipal Hospital, 1-7-9 Hozenji, Kashiwara City, Osaka, 582-0005, Japan.
Department of Surgery, Kashiwara Municipal Hospital, 1-7-9 Hozenji, Kashiwara City, Osaka, 582-0005, Japan.
Int J Surg. 2016 Dec;36(Pt A):335-341. doi: 10.1016/j.ijsu.2016.11.084. Epub 2016 Nov 15.
In Japan, the majority of early gastric cancers (EGCs) are now treated with endoscopic submucosal dissection (ESD). Patients with non-curative lesions treated by ESD are advised to undergo additional surgical resection (ASR) based on guidelines from the Japan Gastroenterological Endoscopy Society (JGES) and Japanese Gastric Cancer Association (JGCA). However, many studies have demonstrated that residual cancer and lymph node metastasis are only rarely found in ASR specimens. Here we retrospectively analyzed the conditions that could enable the avoidance of unnecessary ASR.
The ESD data for 114 absolute indication lesions and 26 lesions of expanded indication lesions were analyzed. The indications and the curability were evaluated according to the JGES/JGCA guidelines.
The rates of non-curative resection and ASR were significantly higher in the expanded indication group compared to the absolute indication group (26.9% and 19.2% vs. 7.9% and 0.9%, respectively). ASR was performed for six patients. Three of their ARS specimens contained neither residual cancer nor lymph node metastasis, and the pathological findings of the preceding ESD specimens deviated slightly from the curative criteria defined by the guidelines. The conditions of the lesions that did not meet the curative criteria were as follows: (1) sm1 invasion of undifferentiated-type lesion <10 mm dia., (2) 21-25 mm dia. mucosal undifferentiated-type lesion, or (3) peacemeal resection with a horizontal margin positive for the mucosal differentiated-type.
These data suggest that a close follow-up without ASR might be appropriate for patients in the above-mentioned three categories after non-curative ESD for EGC.
在日本,大多数早期胃癌(EGC)现在都采用内镜黏膜下剥离术(ESD)进行治疗。根据日本胃肠内镜学会(JGES)和日本胃癌协会(JGCA)的指南,对接受 ESD 治疗但存在非治愈性病变的患者建议进行额外的手术切除(ASR)。然而,许多研究表明,在 ASR 标本中仅很少发现残留癌症和淋巴结转移。在此,我们回顾性分析了可以避免不必要的 ASR 的情况。
分析了 114 例绝对适应证病变和 26 例扩大适应证病变的 ESD 数据。根据 JGES/JGCA 指南评估适应证和可治愈性。
扩大适应证组的非治愈性切除和 ASR 率明显高于绝对适应证组(26.9%和 19.2%比 7.9%和 0.9%)。对 6 例患者进行了 ASR。他们的 6 例 ASR 标本均未发现残留癌或淋巴结转移,且先前 ESD 标本的病理发现与指南定义的治愈标准略有偏离。不符合治愈标准的病变情况如下:(1)sm1 侵犯未分化型病变<10mm 直径,(2)21-25mm 直径黏膜未分化型病变,或(3)水平切缘阳性的局灶性黏膜分化型切除。
这些数据表明,对于 EGC 接受非治愈性 ESD 治疗后的上述三类患者,密切随访而无需进行 ASR 可能是合适的。